168 related articles for article (PubMed ID: 24991716)
21. Erwinia asparaginase in pediatric acute lymphoblastic leukemia.
Salzer W; Seibel N; Smith M
Expert Opin Biol Ther; 2012 Oct; 12(10):1407-14. PubMed ID: 22946493
[TBL] [Abstract][Full Text] [Related]
22. Safety profile of asparaginase Erwinia chrysanthemi in a large compassionate-use trial.
Plourde PV; Jeha S; Hijiya N; Keller FG; Silverman LB; Rheingold SR; Dreyer ZE; Dahl GV; Mercedes T; Lai C; Corn T
Pediatr Blood Cancer; 2014 Jul; 61(7):1232-8. PubMed ID: 24436152
[TBL] [Abstract][Full Text] [Related]
23. Activity and Toxicity of Intravenous Erwinia Asparaginase Following Allergy to E. coli-Derived Asparaginase in Children and Adolescents With Acute Lymphoblastic Leukemia.
Vrooman LM; Kirov II; Dreyer ZE; Kelly M; Hijiya N; Brown P; Drachtman RA; Messinger YH; Ritchey AK; Hale GA; Maloney K; Lu Y; Plourde PV; Silverman LB
Pediatr Blood Cancer; 2016 Feb; 63(2):228-33. PubMed ID: 26376459
[TBL] [Abstract][Full Text] [Related]
24. Successful treatment with apixaban of sinus venous thrombosis due to pegylated asparaginase in a young adult with T cell acute lymphoblastic leukemia: case report and review of management.
Talamo L; Douvas M; Macik BG; Ornan D
Ann Hematol; 2017 Apr; 96(4):691-693. PubMed ID: 28132079
[No Abstract] [Full Text] [Related]
25. Use of PEG-asparaginase in newly diagnosed adults with standard-risk acute lymphoblastic leukemia compared with E. coli-asparaginase: a retrospective single-center study.
Liu WJ; Wang H; Wang WD; Zhu MY; Liu CC; Wang JH; Lu Y
Sci Rep; 2016 Dec; 6():39463. PubMed ID: 28000713
[TBL] [Abstract][Full Text] [Related]
26. Impact of clinical and subclinical hypersensitivity to asparaginase in acute lymphoblastic leukemia.
Asselin BL; Fisher V
Clin J Oncol Nurs; 2014 Dec; 18(6):E107-12. PubMed ID: 25427712
[TBL] [Abstract][Full Text] [Related]
27. Acute parotitis during induction therapy including L-asparaginase in acute lymphoblastic leukemia.
Sica S; Pagano L; Salutari P; Di Mario A; Rutella S; Leone G
Ann Hematol; 1994 Feb; 68(2):91-2. PubMed ID: 8148421
[TBL] [Abstract][Full Text] [Related]
28. How to manage asparaginase hypersensitivity in acute lymphoblastic leukemia.
Burke MJ
Future Oncol; 2014 Dec; 10(16):2615-27. PubMed ID: 24983955
[TBL] [Abstract][Full Text] [Related]
29. Pharmacokinetics and drug monitoring of L-asparaginase treatment.
Boos J
Int J Clin Pharmacol Ther; 1997 Mar; 35(3):96-8. PubMed ID: 9088996
[TBL] [Abstract][Full Text] [Related]
30. Efficacy and safety of native versus pegylated Escherichia coli asparaginase for treatment of adults with high-risk, Philadelphia chromosome-negative acute lymphoblastic leukemia.
Ribera JM; Morgades M; Montesinos P; Martino R; Barba P; Soria B; Bermúdez A; Moreno MJ; González-Campos J; Vives S; Gil C; Abella E; Guàrdia R; Martínez-Carballeira D; Martínez-Sánchez P; Amigo ML; Mercadal S; Serrano A; López-Martínez A; Vall-Llovera F; Sánchez-Sánchez MJ; Peñarrubia MJ; Calbacho M; Méndez JA; Bergua J; Cladera A; Tormo M; García-Belmonte D; Feliu E; Ciudad J; Orfao A;
Leuk Lymphoma; 2018 Jul; 59(7):1634-1643. PubMed ID: 29165013
[TBL] [Abstract][Full Text] [Related]
31. In brief: asparaginase Erwinia chrysanthemi (Erwinaze) for ALL.
Med Lett Drugs Ther; 2012 Apr; 54(1388):32. PubMed ID: 22499236
[No Abstract] [Full Text] [Related]
32. Thrombosis associated with L-asparaginase therapy and low fibrinogen levels in adult acute lymphoblastic leukemia.
Beinart G; Damon L
Am J Hematol; 2004 Dec; 77(4):331-5. PubMed ID: 15551293
[TBL] [Abstract][Full Text] [Related]
33. Non-randomised study comparing toxicity of Escherichia coli and Erwinia asparaginase in children with leukaemia.
Eden OB; Shaw MP; Lilleyman JS; Richards S
Med Pediatr Oncol; 1990; 18(6):497-502. PubMed ID: 2233523
[TBL] [Abstract][Full Text] [Related]
34. Effect of glucocorticoids, E. coli- and Erwinia L-asparaginase on hemostatic proteins in children with acute lymphoblastic leukemia.
Mall V; Thomas KB; Sauter S; Niemeyer CM; Sutor AH
Klin Padiatr; 1999; 211(4):205-10. PubMed ID: 10472551
[TBL] [Abstract][Full Text] [Related]
35. L-asparaginase-induced reversible posterior leukoencephalopathy syndrome in a child with acute lymphoblastic leukemia.
Rathi B; Azad RK; Vasudha N; Hissaria P; Sawlani V; Gupta RK
Pediatr Neurosurg; 2002 Oct; 37(4):203-5. PubMed ID: 12372914
[TBL] [Abstract][Full Text] [Related]
36. An antithrombin replacement strategy during asparaginase therapy for acute lymphoblastic leukemia is associated with a reduction in thrombotic events.
Farrell K; Fyfe A; Allan J; Tait RC; Leach M
Leuk Lymphoma; 2016 Nov; 57(11):2568-74. PubMed ID: 27078747
[TBL] [Abstract][Full Text] [Related]
37. A Randomized Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Recombinant Erwinia Asparaginase (JZP-458) in Healthy Adult Volunteers.
Lin T; Hernandez-Illas M; Rey A; Jenkins J; Chandula R; Silverman JA; Choi MR
Clin Transl Sci; 2021 May; 14(3):870-879. PubMed ID: 33278328
[TBL] [Abstract][Full Text] [Related]
38. Incidence of asparaginase-related hepatotoxicity, pancreatitis, and thrombotic events in adults with acute lymphoblastic leukemia treated with a pediatric-inspired regimen.
Christ TN; Stock W; Knoebel RW
J Oncol Pharm Pract; 2018 Jun; 24(4):299-308. PubMed ID: 28355969
[TBL] [Abstract][Full Text] [Related]
39. Premedication prior to PEG-asparaginase is cost-effective in pediatric patients with acute lymphoblastic leukemia.
McCormick M; Lapinski J; Friehling E; Smith K
Pediatr Blood Cancer; 2021 Aug; 68(8):e29051. PubMed ID: 33860989
[TBL] [Abstract][Full Text] [Related]
40. Anti-Erwinia asparaginase antibodies during treatment of childhood acute lymphoblastic leukemia and their relationship to outcome: a case-control study.
Klug Albertsen B; Schmiegelow K; Schrøder H; Carlsen NT; Rosthøj S; Avramis VI; Jakobsen P
Cancer Chemother Pharmacol; 2002 Aug; 50(2):117-20. PubMed ID: 12172975
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
